What is Dinutuximab: Uses, Dosage, Side Effects and More

Dinutuximab is a specialized cancer treatment medication that helps your immune system fight a rare but serious childhood cancer called neuroblastoma. This targeted therapy works by attaching to cancer cells and marking them for destruction by your body's natural defense system.

While the name might sound complicated, think of dinutuximab as a very precise tool that helps doctors treat one of the most challenging cancers that affects children. It's given through an IV in the hospital, where medical teams can monitor your child closely throughout the treatment process.

What is Dinutuximab?

Dinutuximab is a monoclonal antibody medication specifically designed to treat high-risk neuroblastoma in children. It's a laboratory-made protein that mimics your immune system's natural ability to identify and attack cancer cells.

This medication belongs to a class of drugs called immunotherapies, which means it works by boosting your child's immune system rather than directly poisoning cancer cells like traditional chemotherapy. The drug attaches to a specific protein called GD2 that's found on neuroblastoma cancer cells.

Dinutuximab is considered a targeted therapy because it's designed to seek out and bind specifically to neuroblastoma cells while leaving healthy cells largely untouched. This precision helps reduce some of the harsh side effects often seen with other cancer treatments.

What is Dinutuximab Used For?

Dinutuximab is primarily used to treat high-risk neuroblastoma in children who have already completed initial treatment with surgery and high-dose chemotherapy. It's specifically approved for children whose cancer has responded well to first-line treatments.

Neuroblastoma is a cancer that develops in nerve tissue and most commonly affects children under 5 years old. High-risk neuroblastoma means the cancer has features that make it more likely to come back or spread to other parts of the body.

Your child's oncologist will recommend dinutuximab as part of what's called maintenance therapy. This means it's used after the main treatment to help prevent the cancer from returning. The goal is to catch and destroy any cancer cells that might still be hiding in your child's body.

In some cases, doctors might also use dinutuximab for relapsed neuroblastoma, meaning the cancer has come back after initial treatment. However, this use is less common and depends on your child's specific situation.

How Does Dinutuximab Work?

Dinutuximab works by acting like a guided missile that targets neuroblastoma cancer cells specifically. It attaches to a protein called GD2 that sits on the surface of these cancer cells like a bulls-eye.

Once dinutuximab locks onto the GD2 protein, it signals your child's immune system to attack and destroy the marked cancer cell. Think of it as putting a bright flag on the cancer cell that says "destroy me" to the immune system's natural killer cells.

This medication is considered a strong and effective treatment for neuroblastoma. While it's powerful, it's also very specific in its targeting, which helps protect healthy cells from damage.

The process happens gradually over time, which is why dinutuximab is given in multiple cycles over several months. Each treatment session gives the immune system more opportunities to find and eliminate cancer cells throughout your child's body.

How Should I Take Dinutuximab?

Dinutuximab is always given in a hospital setting through an intravenous (IV) line directly into your child's bloodstream. You cannot give this medication at home, as it requires careful medical supervision and monitoring.

Before each infusion, your child will receive pre-medications to help prevent allergic reactions and manage pain. These typically include antihistamines, pain relievers, and sometimes steroids. The medical team will make sure your child is as comfortable as possible.

During the infusion, which usually takes 10-20 hours, nurses will monitor your child's vital signs regularly. The medication is given slowly to reduce the risk of severe reactions. Most children receive the treatment over multiple days in the hospital.

Your child doesn't need to eat specific foods before treatment, but staying well-hydrated is important. The medical team will provide IV fluids as needed and may recommend light meals if your child feels up to eating.

How Long Should I Take Dinutuximab For?

The typical treatment course involves 5 cycles of dinutuximab given over about 6 months. Each cycle lasts about 24 days, with treatment given on specific days followed by rest periods to allow your child's body to recover.

Your child's oncologist will determine the exact schedule based on how well they're responding to treatment and how they're handling the side effects. Some children may need longer breaks between cycles if they experience significant side effects.

It's crucial to complete the full course of treatment even if your child seems to be doing well. Stopping early could allow cancer cells to survive and potentially cause the cancer to return.

The medical team will monitor your child's progress through regular scans and blood tests throughout the treatment period. These help determine if the medication is working effectively and if any adjustments need to be made.

What Are the Side Effects of Dinutuximab?

Dinutuximab can cause side effects, and it's important to understand that experiencing them doesn't mean the treatment isn't working. The medical team is well-prepared to manage these effects and keep your child as comfortable as possible.

Pain is the most common and often the most challenging side effect of dinutuximab. This happens because the medication can affect nerve endings, causing significant discomfort during and after infusions.

Here are the most common side effects you might notice:

• Severe pain, especially in the abdomen, chest, or extremities
• Fever and chills during or after infusion
• Allergic reactions including rash, itching, or difficulty breathing
• Low blood pressure
• Nausea and vomiting
• Diarrhea
• Decreased appetite
• Fatigue and weakness

The medical team will provide strong pain medications and other supportive care to help manage these effects. Most side effects are temporary and improve between treatment cycles.

More serious but less common side effects can include:

• Severe allergic reactions requiring emergency treatment
• Nerve damage causing long-term pain or weakness
• Eye problems including blurred vision or light sensitivity
• Hearing changes or ringing in the ears
• Kidney problems
• Serious infections due to weakened immune system

Rare but serious complications might include capillary leak syndrome, where fluid leaks from blood vessels into surrounding tissues, causing swelling and breathing difficulties. The medical team monitors for this carefully during treatment.

Who Should Not Take Dinutuximab?

Dinutuximab is not suitable for everyone, and your child's oncologist will carefully evaluate whether it's the right treatment option. Children with certain health conditions may not be able to receive this medication safely.

Your child should not receive dinutuximab if they have a known severe allergy to the medication or any of its components. The medical team will discuss your child's allergy history thoroughly before starting treatment.

Children with active, uncontrolled infections typically cannot start dinutuximab treatment. The medication can affect the immune system, making it harder to fight off infections effectively.

Certain heart, kidney, or liver problems may make dinutuximab too risky for some children. The medical team will run comprehensive tests to ensure your child's organs are functioning well enough to handle the treatment.

Children who have recently received live vaccines should wait before starting dinutuximab, as the medication can interfere with vaccine effectiveness and potentially cause complications.

Dinutuximab Brand Names

Dinutuximab is sold under the brand name Unituxin in the United States. This is the most commonly used version of the medication in American hospitals and cancer centers.

In Europe and some other countries, you might see a similar medication called dinutuximab beta, which is sold under the brand name Qarziba. While very similar, these are technically different formulations of the same type of treatment.

Your child's medical team will use whichever version is available and approved in your location. Both versions work in essentially the same way and have similar effectiveness for treating neuroblastoma.

Dinutuximab Alternatives

Currently, there are no direct alternatives to dinutuximab for treating high-risk neuroblastoma. It's the only FDA-approved immunotherapy specifically designed for this type of cancer in children.

However, if your child cannot receive dinutuximab, the medical team might consider other treatment approaches. These could include additional chemotherapy regimens, radiation therapy, or participation in clinical trials testing new treatments.

Some children might receive isotretinoin (a form of vitamin A) as an alternative maintenance therapy, though this is generally considered less effective than dinutuximab for high-risk cases.

The choice of alternative treatments depends heavily on your child's specific situation, including their age, overall health, and how their cancer has responded to previous treatments.

Is Dinutuximab Better Than Other Neuroblastoma Treatments?

Dinutuximab represents a significant advancement in neuroblastoma treatment and has shown superior results compared to older maintenance therapies. Studies have demonstrated that children who receive dinutuximab are more likely to remain cancer-free longer than those who receive isotretinoin alone.

Before dinutuximab was available, doctors primarily used isotretinoin for maintenance therapy after initial treatment. While isotretinoin helps, clinical trials have shown that adding dinutuximab to the treatment plan significantly improves outcomes.

The combination of dinutuximab with isotretinoin has become the new standard of care for high-risk neuroblastoma because it's more effective at preventing cancer recurrence. This doesn't mean other treatments are bad, but rather that dinutuximab offers children the best chance for long-term survival.

However, the "best" treatment always depends on your individual child's situation. Some children may not be candidates for dinutuximab due to other health factors, and the medical team will work with you to find the most appropriate treatment plan.